Drug Trial Radar · NCT01421693
Gatifloxacin Versus Ceftriaxone in the Treatment of Enteric Fever
Last checked: Nov 20, 2026Latest source record: Oct 4, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
300
Actual
Start
Sep 2011
Primary completion
Jul 2014
Study completion Jan 2015
Sponsor
- Lead sponsor
- Oxford University Clinical Research Unit, VietnamAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- University of Oxford; Patan Academy of Health Sciences, Nepal; Patan Hospital, Nepal; Civil Hospital, Nepal
- First posted
- Aug 23, 2011
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 2 years, up to 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The investigators aim to compare two antibiotic treatments for enteric (typhoid) fever. Three hundred patients at Patan Hospital will be enrolled in the study. Patients will be assigned to one of the two treatments by chance and followed for 6 months. The two treatment groups will be compared to see which treatment is more likely to make the patient better.
Conditions
- Enteric Fever
- Typhoid Fever
Interventions
CeftriaxoneDrug
* ≥2-\<14 years - 60mg/kg/ once daily for 7 days * 14 years and older - 2g once daily for 7 days * Intravenous infusion. Vials of crystalline powder.
GatifloxacinDrug
Gatifloxacin 10 mg/kg/day for 7 days. Tablets for oral administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of treatment failureTime frame: upon occurance, within 28 days
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Civil Hospital
Kathmandu, Nepal
Patan Hospital
Kathmandu, Nepal
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.